Vinorelbine Ditartrate
Adenosquamous Lung Carcinoma
National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Adenosquamous Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cis-Diamminedichloroplatinum Ii Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
Carboplatin NRG Oncology | Phase 3 | BB |
Gefitinib National Cancer Institute (NCI) | Phase 3 | BB |
Shark Cartilage Extract National Cancer Institute (NCI) | Phase 3 | BB |
Cyclophosphamide H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | B |
View all 22 →
Same molecule, other indications
Vinorelbine Ditartrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →